Medikamentenresistenz und Knappheit an Antibiotika: Neuer Bericht zeigt, wie man den Arzneimittelmarkt wieder aufbauen kann

Im neusten Bericht „Shortages, stockouts and scarcity: the issues facing the security of antibiotic supply and the role for pharmaceutical companies“ warnt die Access to Medicine Foundation davor, dass Antibiotika-Lieferketten am Rande des Zusammenbruchs stehen. Dies gefährdet die medizinische Grundversorgung. Dringende Maßnahmen sind erforderlich, um den Antibiotika-Markt wieder aufzubauen. Der Bericht zeigt, wie Pharmaunternehmen auf diese Entwicklungen reagieren.
Continue reading

Drug resistance and antibiotic shortages

Today, the Access to Medicine Foundation warns that antibiotic supply chains are on the brink of collapse, putting basic healthcare at risk, in a new white paper titled “Shortages, stockouts and scarcity: the issues facing the security of antibiotic supply and the role for pharmaceutical companies”. Urgent action is needed to rebuild the antibiotics market. The paper shows how some pharmaceutical companies are responding.
Continue reading

Superbugs: first independent comparison of pharma companies’ efforts to address drug-resistant infections

For the first time, the Antimicrobial Resistance Benchmark has independently evaluated what pharmaceutical companies are doing to bring antimicrobial resistance (AMR) under control. AMR is a global issue: antibiotics are being overused, which is causing them to become less effective. To bring it under control, action is needed from all sides, including from the pharma sector. This is the first report to independently compare how pharmaceutical companies are tackling AMR. It has evaluated 30 pharmaceutical companies, including those with the largest R&D divisions, the largest market presence, and specific expertise in developing critically needed medicines and vaccines.
Continue reading

New: latest framework for action by pharmaceutical companies on access to medicine

Today, the Access to Medicine Foundation publishes the methodology for the 2018 Access to Medicine Index. It presents the latest good practice framework for action by pharmaceutical companies working to improve access to medicine.
Continue reading

Now online: first independent framework for assessing pharma company action on AMR

Today, the Access to Medicine Foundation publishes the methodology for its 2018 Antimicrobial Resistance Benchmark. It is the first independently developed framework for evaluating how pharmaceutical companies are taking action to limit antimicrobial resistance (AMR).
Continue reading

New study finds wide variety in pharma companies’ cancer access programmes

The Access to Medicine Foundation has systematically mapped how large research-based pharmaceutical companies are responding to the growing cancer crisis in low and lower-middle income countries.
Continue reading

New Access to Vaccines Index reveals first landscape of vaccine company actions to improve immunisation coverage.

The 2017 Access to Vaccines Index reveals the first landscape of industry activity to improve immunisation coverage. It finds a high level of diversity in how vaccine companies are improving access to vaccines for people living in poorer countries. This diversity is generally linked to the size of their portfolios and pipelines.
Continue reading

Nieuwe Access to Vaccines Index geeft inzicht in wat vaccinbedrijven doen om inentingsgraad wereldwijd te verbeteren

De eerste editie van de Access to Vaccines Index geeft een gedetailleerd overzicht van wat de vaccin industrie doet om de vaccinatiegraad te verbeteren. De index laat grote verschillen zien in de manieren waarop vaccinontwikkelaars en -fabrikanten meer toegang tot vaccins creëren voor mensen in lage- en middeninkomenslanden. Deze verschillen hangen sterk samen met de omvang van het productportfolio van de fabrikanten en wat er in de R&D-pijplijn zit.
Continue reading

Le nouvel Indice d’Accès aux Vaccins révèle le premier panorama des actions des laboratoires de vaccins pour améliorer la couverture vaccinale.

L’Indice d’Accès aux Vaccins (Access to Vaccines Index) de 2017 révèle le premier panorama de l’activité industrielle pour améliorer la couverture vaccinale. Il constate de grandes différences au niveau de la manière dont les laboratoires de vaccins améliorent l’accès aux vaccins pour les populations vivant dans les pays les plus pauvres. Ces différences sont généralement liées à l’ampleur des portefeuilles et des filières de recherche des laboratoires.
Continue reading

Pharmaceutical companies’ strategies for reaching the poor are maturing. But expansion is gradual.

Pharmaceutical companies are getting more sophisticated in the way they get their products to poor people and are addressing global health priorities. However, good practice is limited to a narrow range of products and countries. Opportunities to expand such targeting of efforts are yet to be realised.
Continue reading

Strategie van farmaceutische bedrijven om de armen te bereiken wordt volwassener. Maar de uitbreiding gaat stapsgewijs.

De manier waarop farmaceutische bedrijven medicijnen beschikbaar maken voor mensen in arme landen en wereldwijde gezondheidsprioriteiten aanpakken wordt steeds geavanceerder. De schaal waarop dit gebeurt beperkt zich echter nog tot een relatief klein aantal producten en landen.
Continue reading

Access to Medicine Index 2016: Pharmaunternehmen verbessern ihre Strategien, um Arme zu erreichen – doch der Ausbau ist schleichend

Pharmazeutische Unternehmen werden immer besser darin, ihre Produkte armen Menschen zur Verfügung zu stellen und globale Gesundheitsprobleme anzugehen. Trotzdem beschränken sich die bewährten Verfahren auf wenige Produkte und Länder.
Continue reading

Les stratégies des laboratoires pharmaceutiques pour atteindre les populations pauvres sont en voie de maturation. Cependant, leur application ne s’étend que graduellement.

Pour mettre leurs produits à la portée des populations pauvres, les laboratoires pharmaceutiques adoptent des stratégies plus complexes, qui répondent notamment aux priorités en matière de santé mondiale. Cependant, les bonnes pratiques se limitent à un nombre restreint de produits et de pays. Il reste encore à créer les opportunités qui permettront leur élargissement.
Continue reading

Access to Medicine Foundation announces 2016 Access to Medicine Index (Japanese News Release)

The Access to Medicine Foundation has announced today the publication of the 2016 Access to Medicine Index. GSK leads the Index for the fifth time and of the Japanese companies participating in the Index, Eisai ranked 11th while Takeda rose significantly, up five positions to rank 15th.
Continue reading

Greater emphasis on how pharmaceutical companies perform in access to medicine: methodology for the 2016 Access to Medicine Index

The Access to Medicine Index ranks the world’s leading pharmaceutical companies on their efforts to improve access to life-saving drugs, vaccines, diagnostic tests and other health technologies in developing countries.
Continue reading

Pharmaceutical industry doing more to improve access to medicine in developing countries; performance on some aspects lags

The world’s leading pharmaceutical companies are doing more to improve access to medicine in developing countries, with a raft of new initiatives, scale-ups and innovations over the last two years. However, the industry struggles to perform well in some practices that matter, according to the 2014 Access to Medicine Index, published Monday.
Continue reading

Sign up to receive updates about our work.